Hi folks.  Here are the top regulatory news stories for this week: Pfizer Inc. announced today that the FDA has approved IXIFI™ a chimeric human-murine monoclonal antibody (mAb) against tumor necrosis factor, as a biosimilar to Remicade® (infliximab) for all eligible indications of the reference product.  https://www.firstwordpharma.com/node/1529996#axzz51FIjJ9GS The FDA approved Sanofi’s rapid-acting insulin analog Admelog[…]